- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07811219
RESP-FIT: A Respiratory Muscle Strength Training Intervention for COPD
10. september 2026 oppdatert av: Medical University of South Carolina
Individuals with chronic obstructive pulmonary disease (COPD) often experience dyspnea, low physical activity, and reduced quality of life.
RESP-FIT is a randomized controlled trial evaluating a remotely delivered respiratory muscle strength training intervention combined with mobile health tools to improve dyspnea, respiratory muscle strength, and physical activity in adults with COPD.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
This randomized, parallel-group clinical trial will enroll adults with COPD and assign them 1:1 to either the RESP-FIT intervention or enhanced usual care.
The RESP-FIT intervention includes respiratory muscle strength training using a commercially available inspiratory muscle trainer, remote spirometry, physical activity monitoring, ecological momentary assessment of symptoms, and a mobile application for monitoring and feedback.
Primary and secondary outcomes include dyspnea, dyspnea-related kinesiophobia, respiratory muscle strength, physical activity, lung function, and quality of life, assessed over a 6-month follow-up period.
All study activities are conducted remotely.
Studietype
Intervensjonell
Registrering (Antatt)
288
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Mary Chris S. Pittman, BA
- Telefonnummer: 8437923512
- E-post: pittmama@musc.edu
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age ≥40 years
- Clinical diagnosis of COPD
- Ability to provide informed consent
- Willingness to use mobile health devices and apps
- Access to Wi-Fi and mailing address in the U.S.
Exclusion Criteria:
- Cognitive impairment preventing participation
- Active substance abuse
- Other significant respiratory disease
- Concurrent enrollment in conflicting COPD or behavioral intervention trials
- Non-English speaking
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: RESPFIT Intervention Arm
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using an activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period.
Participants will be asked to record training sessions and symptoms using the mobile application.
The intervention period will last 6 months, with the primary endpoint occurring at 3 months following baseline.
Outcome assessments will occur at baseline and at 1, 2, 3, and 6 months.
|
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), EMA symptom management through the RESP-FIT app, ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using the Garmin activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period of 6 months.
Participants will also be asked to record training sessions and symptoms using the mobile application.
Participants will receive on-going support and monitoring from study personnel for the first 3 months and can use app and devices at will for the next 3 months until the 6 month assessment period when the study procedures end.
|
|
Ingen inngripen: No Intervention Enhanced Usual Care Group
Participants randomized to the control group will receive enhanced usual care (eUC).
This consists of their standard COPD management provided by their healthcare providers along with the mobile app for remote spirometry and symptom tracking and physical activity monitoring using the Garmin wearable activity tracker.
Control group participants will also receive publicly available COPD educational materials (via COPD Foundation resources).
Providing an activity monitor to both groups allows the research team to account for potential effects of activity monitoring on physical activity behavior.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Maximal Inspiratory Pressure (PImax)
Tidsramme: Baseline to 3 Months
|
Maximal inspiratory pressure measured using the POWERbreathe Smart Adaptor digital pressure transducer connected to a mouthpiece.
|
Baseline to 3 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Modified Borg Dyspnea Scale Score
Tidsramme: Baseline to 3 Months
|
Dyspnea severity assessed using the Modified Borg Scale delivered through ecological momentary assessment (EMA) within the study mobile application.
Scores range from 0-10, with 0 indicating no breathlessness and 10 indicating maximal breathlessness.
Higher scores indicate greater dyspnea severity.
|
Baseline to 3 Months
|
|
Change in Breathlessness Beliefs Questionnaire (BBQ) Score
Tidsramme: Baseline to 3 Months
|
Dyspnea-related kinesiophobia assessed using the Breathlessness Beliefs Questionnaire (BBQ), a validated 11-item instrument that measures dysfunctional beliefs about breathlessness related to physical activity.
Items are rated on a 5-point scale, yielding a total score ranging from 11-55, with higher scores indicating stronger beliefs about breathlessness and greater dyspnea-related fear and activity avoidance.
|
Baseline to 3 Months
|
|
Change in Modified Medical Research Council (mMRC) Dyspnea Scale Score
Tidsramme: Baseline to 3 Months
|
Breathlessness measured using the Modified Medical Research Council (mMRC) Dyspnea Scale, a 5-grade scale that assesses the degree to which breathlessness limits daily physical activities.
Scores range from 0-4, with higher scores indicating breathlessness that prevents leaving the house or occurring during dressing/undressing.
Higher scores indicate worse dyspnea-related functional limitation.
|
Baseline to 3 Months
|
|
Change in PROMIS Dyspnea-Related Activity Avoidance Score
Tidsramme: Baseline to 3 Months
|
Activity avoidance due to breathing discomfort assessed using the PROMIS Dyspnea-Related Activity Avoidance instrument.
This is a 5 point Likert scale with 3 items measuring avoidance of activities due to shortness of breath or phsyical limitations over the past 7 days, scored from 0 (not at all) to 4 (very much), yielding total raw score range of 0-12.
Higher scores indicate greater dyspnea-related task avoidance.
|
Baseline to 3 Months
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Tidsramme: Baseline to 3 Months
|
Respiratory-related quality of life assessed using the St. George's Respiratory Questionnaire (SGRQ) for COPD.
This is contains 40 items assessing three domains (symptoms, activity, and impact) and a total score ranging from 0-100, with 0 indicating no impairment and 100 indicating maximum impairment.
Higher scores indicate greater impairment in respiratory related quality of life.
|
Baseline to 3 Months
|
|
Change in Average Daily Step Count
Tidsramme: Baseline to 3 Months
|
Physical activity measured using a Garmin wearable activity monitor, with daily steps captured numerically in number of steps.
|
Baseline to 3 Months
|
|
Change in CAPTURE Score
Tidsramme: Baseline to 3 Months
|
COPD symptoms and exacerbation risk assessed using the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) questionnaire.
This is a 5 item instrument assessing respiratory symptoms, risk exposures, recent acute respiratory illnesses with a total score range of 0-6, with higher scores indicating greater likelihood of clinically significant COPD and exacerbation risk.
|
Baseline to 3 Months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Qualitative Measures
Tidsramme: 3 months
|
Semi-structured interviews assessing intervention accessibility, usability, symptom monitoring, dyspnea-related activity avoidance, disease self-management, and overall participant experiences with RESP-FIT
|
3 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Sarah Miller, PhD, RN, Medical University of South Carolina
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
15. september 2026
Primær fullføring (Antatt)
15. april 2030
Studiet fullført (Antatt)
15. mai 2031
Datoer for studieregistrering
Først innsendt
21. august 2026
Først innsendt som oppfylte QC-kriteriene
4. september 2026
Først lagt ut (Faktiske)
10. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00149990
- 1R01NR021347-01A1 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Study Protocol
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Ja
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .